The study analyzed 33 healthy adult participants in the U.S. National Institute of Health-led phase I study of Moderna's COVID-19 vaccine at six months following a second 100 µg dose (day 209). Antibody decay was estimated using two approaches and was consistent with published observations of convalescent patients with COVID-19 through eight months after symptom onset, the company said in a statement.

Studies monitoring immune responses beyond six months are ongoing. Out of an abundance of caution, Moderna is also pursuing a clinical development strategy against emerging variants.

Additionally, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will conduct a phase I clinical trial to assess the company's monovalent and multivalent modified mRNA-1273 vaccines as a primary series in naive individuals and as a booster vaccine in those previously vaccine with mRNA-1273.

Moderna announces administration of pediatric COVID-19 vaccine doses
Moderna announced that the first participants have been dosed in its phase II/III study of its pediatric messenger RNA (mRNA) COVID-19 vaccine candidate,...

Takeda, IDT help manufacture Janssen COVID-19 vaccine
Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.

Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.

Can a single dose of a vaccine designed as 2 doses be effective?
Researchers suggested that two doses of a COVID-19 vaccine are more protective than a single dose, even if the interdose period is longer than recommended....

Chromatography drives research fight against SARS-CoV-2 virus
As the battle against the deadly SARS-CoV-2 virus continues, researchers are relying on analytical laboratory techniques like chromatography to provide...